Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
Authors
Keywords
-
Journal
Drug Target Insights
Volume 17, Issue -, Pages 49-53
Publisher
Aboutscience Srl
Online
2023-05-01
DOI
10.33393/dti.2023.2529
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus
- (2021) Naokatsu Ando et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Naïve and Switch Scenarios in HIV-Infected Patients
- (2021) Maria Saumoy et al. Journal of Clinical Medicine
- Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy
- (2021) Suzan Dijkstra et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
- (2019) NEW ENGLAND JOURNAL OF MEDICINE
- Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients
- (2019) Sebastiano Rizzardo et al. AIDS
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Weight gain and integrase inhibitors
- (2019) Allison Ross Eckard et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors
- (2018) David R Bakal et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
- (2018) Lucia Taramasso et al. BMC INFECTIOUS DISEASES
- Brief Report
- (2017) Jamison Norwood et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Weight Gain: A Possible Side Effect of All Antiretrovirals
- (2017) Lucia Taramasso et al. Open Forum Infectious Diseases
- Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada
- (2016) John R. Koethe et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia
- (2016) Pornpimol Thamrongwonglert et al. HIV CLINICAL TRIALS
- Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
- (2015) Romina Quercia et al. CLINICAL DRUG INVESTIGATION
- Dolutegravir: A Next-Generation Integrase Inhibitor for Treatment of HIV Infection
- (2014) D. A. Osterholzer et al. CLINICAL INFECTIOUS DISEASES
- Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
- (2014) Anton Pozniak et al. LANCET INFECTIOUS DISEASES
- Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study
- (2014) Barbara Hasse et al. Open Forum Infectious Diseases
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK
- (2011) Jürgen K. Rockstroh et al. CLINICAL INFECTIOUS DISEASES
- Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens
- (2011) P. Maggi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started